Advanced search
Publication Cover
Cancer Investigation Volume 27, 2009 - Issue 9
Submit an article Journal homepage
81
Views
7
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEClinical Translational Therapeutics

Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

A. R. Jazieh
, MD, MPH,
R. KomrokjiUniversity of Cincinnati, Cincinnati, Ohio, USA.
, MD,
A. GuptaUniversity of Cincinnati, Cincinnati, Ohio, USA.
, MD,
S. PatilUniversity of Memphis, Memphis, Tennessee, USA.
, MD,
D. FloraOncology Hematology Oncology Care, Cincinnati, Ohio, USA.
, MD,
M. KnappMid Ohio Hematology Oncology, Columbus, Ohio, USA.
, MD,
M. IssaKing Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.
, MSc &
N. Abdel KarimUniversity of Cincinnati, Cincinnati, Ohio, USA.
, MD show all
Pages 932-936 | Published online: 15 Oct 2009
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m2 day 1 & 8 and Irinotecan 100 mg/m2 day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10%) experienced partial response and 14 (70%) experienced stable disease. The median time to disease progression was 4 months (95% CI: 2.8–6.6). The 1 year and 2 year survival rates were 36% and 27%, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.